Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
29.05.2017
Atox Bio’s Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
Ness Ziona, Israel and Chapel Hill, NC –May 23, 2017 – Atox Bio today announced that the Phase 3 ACCUTE study, evaluating Reltecimod (previously AB103) in patients with Necrotizing Soft Tissue Infections, will continue as planned without modification based on the successful completion of a pre-specified futility analysis.  The recommendation was made by the independent Data Monitoring Committee (DMC) after evaluating efficacy and safety data from the first 102 patients enrolled.
Dato
22.05.2017
BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute

FORTIFY trial to assess CERAMENT G as part of the surgical repair of severe tibial fractures.

Lund, Sweden, 22 May 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced that the first patient has been enrolled by Dr Ravi Karia at the  University of Texas Health Science Center at San Antonio into the company's pivotal Investigational Device Exemption (IDE) trial:  A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures (the FORTIFY trial: ClinicalTrials.gov Identifier: NCT02820363). 

Dato
15.05.2017
Imara Receives Rare Pediatric Disease Designation from FDA for Lead Product Candidate IMR-687 for Sickle Cell Disease

Cambridge, Mass., May 15, 2017 – Imara Inc, a biotechnology company dedicated to developing novel therapeutics for patients with sickle cell disease (SCD) and other hemoglobinopathies, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to IMR-687, the company’s lead product candidate. IMR-687 is the first SCD candidate to be designated as a drug for a rare pediatric disease, and this designation builds upon, and is complimentary to, the FDA’s earlier grant of Orphan designation. 

Dato
08.05.2017
Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease
- Pivotal Trial of Teprotumumab in Thyroid Eye Disease (TED) Expected to Begin in Second Half of 2017    
- Teprotumumab Phase 2 Trial Results Recently Published in The New England Journal of Medicine    


DUBLIN, Ireland, May 08, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has agreed to acquire River Vision Development Corp. ("River Vision") and its development-stage medicine teprotumumab (RV001), a fully human monoclonal antibody (mAb) currently in development for Thyroid Eye Disease (TED), a rare, autoimmune inflammatory disorder.

Dato
28.04.2017
Lennart Johansson to join BONESUPPORT™ Board of Directors
Lund, Sweden, 28th April, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces the election of Lennart Johansson to its Board of Directors.
Dato
27.04.2017
John Tucker appointed as Chief Executive Officer of scPharmaceuticals
LEXINGTON, Mass., April 26, 2017 /PRNewswire/ -- scPharmaceuticals, Inc. a privately held biopharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, announced the appointment of John Tucker as president and chief executive officer, effective immediately.  Mr. Tucker was also elected to the board of directors of scPharmaceuticals.
Dato
18.04.2017
BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer

Lund, Sweden, 11th April, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces the appointment of Michael Diefenbeck MD PhD as Chief Medical Officer.

Dr Diefenbeck founded Scientific Consulting in Orthopaedic Surgery in 2014 and has worked for BONESUPPORT on a range of clinical projects related to CERAMENT™ as an independent clinical advisor. 

Dato
06.04.2017
ICONIC THERAPEUTICS APPOINTS JULIA P. GREGORY TO BOARD OF DIRECTORS
South San Francisco, April 6, 2017 – – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today the addition of Julia P. Gregory to the company’s Board of Directors.
Dato
04.04.2017
Sucampo Acquires Vtesse Inc.
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, and Vtesse Inc. (Vtesse), a privately-held rare disease company, today  announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand;  no  external  financing  was utilized.

Dato
16.03.2017
BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award
Lund, Sweden, 16 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that its founder Lars Lidgren, is a member of a  group of Swedish and US Knee and Hip surgeons from Lund and Gothenburg, Sweden, Boston and Rochester U.S. that has received the 2017 OREF Clinical Research Kappa Delta Award. The award was made for the group’s outstanding research contribution leading to improved prosthetic survival and patient outcomes.
1 2 3 4 5 6 7 8 9 10 Næste 10 Næste